The literature identifies TNF-α and IL-6 receptor inhibitors to be effective in treating COVID-19 among patients with rheumatic diseases as during recovery of COVID-19, decreased levels of IL-6 and TNF-α increase the total T-cell counts [34,35]. This evidence concerns the gene IL6 and COVID-19.